Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens

Cervical cancer develops as a result of infection with high-risk human papillomavirus (HPV) through persistent expression of early proteins E6 and E7. Our group pioneered a recombinant viral vector system based on Semliki Forest virus (SFV) for vaccination against cervical cancer. The most striking...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stephanie van de Wall, Karl Ljungberg, Peng Peng Ip, Annemarie Boerma, Maria L. Knudsen, Hans W. Nijman, Peter Liljeström, Toos Daemen
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2018-10-01
Colecção:OncoImmunology
Assuntos:
replicon
alphavirus vector
semliki forest virus
hpv
immunotherapy
cancer vaccine
dna vaccine
therapeutic vaccination
Acesso em linha:http://dx.doi.org/10.1080/2162402X.2018.1487913
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados